RxDoctor Payments Data

Candace Phillips

Family · Canton, MINPI 1487334801

Payments from drug & device makers

$1,129in general payments, 2019–2025

Across 38 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$396
  • Stryker$147
  • Sumitomo Pharma America, Inc.$119
  • Coloplast$79
  • Endo Pharmaceuticals Inc.$57
  • Tolmar, Inc.$42
  • plus $289 from 10 others

What the payments were for

  • Food & beverage$1,129100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,129 in reported general payments places this provider in the 70th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$15,483
Medicare patients
103
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron13$11,189
MyrbetriqMirabegron15$8,478
Tamsulosin Hcl112$1,878
Estradiol20$1,522
Methenamine Hippurate17$1,322
Oxybutynin Chloride ErOxybutynin Chloride48$938
Solifenacin Succinate14$459
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$366
Alfuzosin Hcl ErAlfuzosin Hcl16$347
NitrofurantoinNitrofurantoin Macrocrystal13$240
Doxycycline Hyclate57$223
Finasteride20$221
Ciprofloxacin Hcl47$183
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$165
Fluconazole17$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$119$11,18913 claims
Astellas Pharma US IncMyrbetriq$39$8,47815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,657 family providers in Michigan.

Other family in Canton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →